Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. III. Visceral afferent pathways: a source of new therapeutic targets for abdominal pain.

Visceral pain is the major cause of consulting in gastroenterology and the principal symptom of functional bowel disorders. This symptom is often associated with gut hypersensitivity to distension. The use of animal models has recently permitted the identification of some mediators supposed to play a pivotal role in the genesis of visceral hypersensitivity. Serotonin, through different receptor subtypes, as well as kinins and calcitonin gene-related peptide, are known to be involved, but other putative transmitters arise and are new potential targets for the development of efficacious treatments. This themes article addresses both physiological and preclinical issues of interest for the selection of active new drugs in regard to the clinical pharmacology of visceral pain.

[1]  C. Woolf,et al.  Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity , 1999, Nature Neuroscience.

[2]  Y. Hori,et al.  Enkephalinergic neurons express 5-HT3 receptors in the spinal cord dorsal horn: single cell RT-PCR analysis. , 1999, Neuroreport.

[3]  K. Mizumura,et al.  Endogenous nerve growth factor increases the sensitivity to bradykinin in small dorsal root ganglion neurons of adjuvant inflamed rats , 1999, Neuroscience Letters.

[4]  M. I. Smith,et al.  5-HT4 receptor antagonism potentiates inhibition of intestinal allodynia by 5-HT3 receptor antagonism in conscious rats , 1999, Neuroscience Letters.

[5]  S. Fleetwood-Walker,et al.  VIP and PACAP: very important in pain? , 1999, Trends in pharmacological sciences.

[6]  T. Ness.  Kappa opioid receptor agonists differentially inhibit two classes of rat spinal neurons excited by colorectal distention. , 1999, Gastroenterology.

[7]  Leroi,et al.  Octreotide in refractory functional epigastric pain with nutritional impairment—an open study , 1999, Alimentary pharmacology & therapeutics.

[8]  S. Pezet,et al.  Chronic Pain is Associated with Increased TrkA Immunoreactivity in Spinoreticular Neurons , 1999, The Journal of Neuroscience.

[9]  J. Hamon,et al.  Pharmacological properties of trimebutine and N-monodesmethyltrimebutine. , 1999, The Journal of pharmacology and experimental therapeutics.

[10]  G. Gebhart,et al.  Role of neurokinin 3 receptors on responses to colorectal distention in the rat: electrophysiological and behavioral studies. , 1999, Gastroenterology.

[11]  X. J. Song,et al.  Involvement of NMDA and non-NMDA receptors in transmission of spinal visceral nociception in cat. , 1999, Zhongguo yao li xue bao = Acta pharmacologica Sinica.

[12]  A. Ahluwalia,et al.  B1 receptors as a new inflammatory target. Could this B the 1? , 1999, Trends in pharmacological sciences.

[13]  M. Millan,et al.  The induction of pain: an integrative review , 1999, Progress in Neurobiology.

[14]  J. Laird,et al.  Differential effects of N-Methyl-d-aspartate receptor blockade on nociceptive somatic and visceral reflexes , 1999, Pain.

[15]  M. Delvaux,et al.  The κ agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome , 1999 .

[16]  M. Delvaux,et al.  The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. , 1999, Gastroenterology.

[17]  J. Tack,et al.  Role of impaired gastric accommodation to a meal in functional dyspepsia. , 1998, Gastroenterology.

[18]  R. Wachtel,et al.  Inhibition of calcium currents in rat colon sensory neurons by K- but not mu- or delta-opioids. , 1998, Journal of neurophysiology.

[19]  L. Buéno,et al.  Intracolonic glycerol induces abdominal contractions in rats: Role of 5‐HT3 receptors , 1998, Fundamental & clinical pharmacology.

[20]  Picard,et al.  Role of kinin B1 and B2 receptors and mast cells in post intestinal infection‐induced hypersensitivity to distension , 1998, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[21]  H. Gould,et al.  Rapid sodium channel augmentation in response to inflammation induced by complete Freund's adjuvant , 1998, Brain Research.

[22]  M. Delvaux,et al.  Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome , 1998, Alimentary pharmacology & therapeutics.

[23]  R. Quirion,et al.  Calcitonin gene-related peptide in viscerosensitive response to colorectal distension in rats. , 1997, The American journal of physiology.

[24]  R. Shigemoto,et al.  Localisation of neurokinin 3 (NK3) receptor immunoreactivity in the rat gastrointestinal tract , 1997, Cell and Tissue Research.

[25]  L Bueno,et al.  Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. , 1997, Gastroenterology.

[26]  G. Sanger.  5‐Hydroxytryptamine and functional bowel disorders , 1996, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[27]  G. Gebhart,et al.  Intracolonic zymosan produces visceral hyperalgesia in the rat that is mediated by spinal NMDA and non-NMDA receptors , 1996, Brain Research.

[28]  L. Urbán,et al.  New pharmacological strategies for pain relief. , 1996, Annual review of pharmacology and toxicology.

[29]  A. Dickenson.  Spinal cord pharmacology of pain. , 1995, British journal of anaesthesia.

[30]  L. Buéno,et al.  Influence of 5‐HT3 receptor antagonists in visceromotor and nociceptive responses to rectal distension before and during experimental colitis in rats * , 1994, Fundamental & clinical pharmacology.